MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Homozygous deletion of methylthioadenosine phosphorylase (MTAP) is one of the most frequent genetic alterations in glioblastoma (GBM), but its pathologic consequences remain unclear. In this study, we report that loss of MTAP results in profound epigenetic reprogramming characterized by hypomethylation of PROM1/CD133-associated stem cell regulatory pathways. MTAP deficiency promotes glioma stem-like cell (GSC) formation with increased expression of PROM1/CD133 and enhanced tumorigenicity of GBM cells and is associated with poor prognosis in patients with GBM. As a combined consequence of purine production deficiency in MTAP-null GBM and the critical dependence of GSCs on purines, the enriched subset of CD133+ cells in MTAP-null GBM can be effectively depleted by inhibition of de novo purine synthesis. These findings suggest that MTAP loss promotes the pathogenesis of GBM by shaping the epigenetic landscape and stemness of GBM cells while simultaneously providing a unique opportunity for GBM therapeutics. SIGNIFICANCE: This study links the frequently mutated metabolic enzyme MTAP to dysregulated epigenetics and cancer cell stemness and establishes MTAP status as a factor for consideration in characterizing GBM and developing therapeutic strategies.

Duke Scholars

Author Ivan Spasojevic Medicine, Medical Oncology

Author Christopher Pirozzi Pathology

Author Susan Kay Murphy Obstetrics and Gynecology, Reproductive Sciences

Author Roger Edwin McLendon Pathology

Author Henry Seth Friedman Neurosurgery, Neuro-Oncology

Author Allan Howard Friedman Neurosurgery

Author James Emmett Herndon II Biostatistics & Bioinformatics, Division of Biostatistics

Author John Howard Sampson Neurosurgery

Author Stephen Thomas Keir Neurosurgery, Neuro-Oncology

Author Darell Doty Bigner Neurosurgery

Author Yiping He Pathology